Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy

Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy

Abstract Background Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that develops resistance to chemotherapy frequently. Autophagy has been reported as a pro-survival response to chemotherapeutic drugs in TNBC, and suppression of autophagy can be a strategy to ov...

Full description

Bibliographic Details
Main Authors: Shuang Zhang, Yu Dong, Xiuping Chen, Chris Soon Heng TAN, Min Li, Kai Miao, Jia-Hong Lu
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Chinese Medicine
Subjects:
Autophagy inhibition
Toosendanin
Triple-negative breast cancer
Lysosome
Irinotecan
SN-38
Online Access:https://doi.org/10.1186/s13020-022-00605-8

Internet

https://doi.org/10.1186/s13020-022-00605-8

Similar Items